Pfizer Inc. (NYSE:PFE) Holdings Reduced by Cutter & CO Brokerage Inc.

Cutter & CO Brokerage Inc. lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,867 shares of the biopharmaceutical company's stock after selling 11,052 shares during the period. Cutter & CO Brokerage Inc.'s holdings in Pfizer were worth $2,531,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Florida Financial Advisors LLC purchased a new position in Pfizer in the first quarter valued at approximately $246,000. Bleakley Financial Group LLC lifted its holdings in Pfizer by 21.7% in the first quarter. Bleakley Financial Group LLC now owns 102,327 shares of the biopharmaceutical company's stock valued at $2,593,000 after acquiring an additional 18,268 shares during the period. ELCO Management Co. LLC grew its holdings in Pfizer by 23.8% in the first quarter. ELCO Management Co. LLC now owns 31,407 shares of the biopharmaceutical company's stock valued at $796,000 after purchasing an additional 6,031 shares during the last quarter. MQS Management LLC purchased a new position in Pfizer during the 1st quarter valued at about $602,000. Finally, Secured Retirement Advisors LLC grew its holdings in Pfizer by 6.5% during the 1st quarter. Secured Retirement Advisors LLC now owns 8,288 shares of the biopharmaceutical company's stock valued at $210,000 after buying an additional 509 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE traded down $0.30 during mid-day trading on Monday, hitting $25.36. The stock had a trading volume of 25,894,075 shares, compared to its average volume of 45,769,910. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $144.15 billion, a PE ratio of 18.37, a PEG ratio of 0.93 and a beta of 0.58. The company's fifty day simple moving average is $23.89 and its two-hundred day simple moving average is $24.78.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.78%. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

Several research firms recently issued reports on PFE. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Wolfe Research boosted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Morgan Stanley upped their price target on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.